Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: ChinuSFO who wrote (9082)	6/6/1998 10:54:00 AM
From: Gene Voss	Read Replies (1) \| Respond to of 23519

<Regarding the AUA papers> 5 papers concerning Muse were submited to the commitee for presentation selection.3 of these papers showed well controlled positive results and 2 were very negative.Notice the papers chosen for presentation.I"m a poor typist so I can't begin to point out the flaws in these studies but please read the abstracts and you'll see we are not comparing apples to apples in the ED arena when we look at Muse statistics and Viagra claims. Having said that Vivus needs to improve their presentation and sell the product.Papers do influence MDs and prescriptions often follow the data trends.The share price can only improve if MDs write the scripts and sales escalate.I at least hope the trend in sales will reverse but we have to wait ,it won't be over night. GV